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P E R S P E C T I V E S  O N  D I S E A S E
ATARGET for acute intervention in ischaemic strokeis the penumbra, a zone of incomplete cerebral
ischaemia, where neurones are functionally inactive but
still viable. The development of the penumbra is a time-
limited condition where cells will die in the ensuing
hours to days, owing to a cascade of biochemical events,
the so-called ‘ischaemic cascade’ (see Box 1).
Compounds that interfere with these biochemical
steps have been demonstrated to be neuroprotective in
preclinical models of stroke. A fraction of these have
entered clinical development and some of those that
survived early safety trials have been studied in ran-
domized double-blind placebo-controlled efficacy trials
(Phase III trials). Such trials require the courageous par-
ticipation of many stroke patients, a 24-hours-a-day
commitment of physicians from many centres and
usually significant financial investment from a pharma-
ceutical company. The resources required to complete
such a trial are estimated to be about 30–40 million US
dollars1. Despite these efforts, all Phase III trials have
so far failed to demonstrate efficacy of neuroprotective
agents (Table 1).
Na1-channel blockers
The anticonvulsant phenytoin blocks voltage-
dependent Na1 channels and reduces infarct size in
both permanent and reperfusion models of focal brain
ischaemia in rodents24,25. Fosphenytoin is a prodrug of
phenytoin that has been evaluated in a Phase III trial.
Enrolment was halted after 462 patients had been in-
cluded because no differences in primary or secondary
endpoints were found in an interim analysis2.
Ca21-channel blockers
One obvious treatment strategy for stroke involves
the regulation of Ca21 entry into the cell using inhib-
itors of voltage-sensitive Ca21 channels. Nimodipine is
an inhibitor of L-type Ca21 channels, whereas flunarizine
mainly acts as a T-type Ca21-channel blocker26. Both
these compounds can reduce infarct size when admin-
istered shortly after permanent and transient focal cer-
ebral ischaemia26. However, their potency is less than that
of glutamate-receptor antagonists. Nimodipine has been
studied most extensively and, in contrast to its benefi-
cial effects in subarachnoid haemorrhage, it has pro-
duced unimpressive results in acute cerebral ischaemia.
The intravenous administration even worsened outcome
because of detrimental haemodynamic effects8. A meta-
analysis covering nine studies with oral nimodipine
(120 mg/day) suggested a possible benefit when the
drug was given within the first 12 h after onset of symp-
toms27. The VENUS (very early nimodipine use in stroke)
trial, which was conducted to confirm this hypothesis
in a prospective manner, has been stopped because, in
an interim analysis, no benefit of nimodipine became
evident9. Clinical development of flunarizine in stroke
has been suspended after negative results of the FIST
(flunarizine in stroke trial)10.
Glutamate inhibition or GABA stimulation
Inhibitors of glutamate receptors, particularly those
that block NMDA receptors, can reduce infarction vol-
ume and neurological deficits in permanent and re-
perfusion models of focal cerebral ischaemia28. The use
of several NMDA-receptor antagonists was discontinued
in Phase I and Phase II studies because of unacceptable
adverse effects. The major problems with these com-
pounds are psychomimetic effects (agitation, halluci-
nations, paranoia and delirium), sedation, catatonia and
concerns about potential neurotoxicity29. Only selfotel,
a competitive antagonist at the NMDA binding site of
the NMDA receptor, and aptiganel, a non-competitive
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Clinical trials with neuroprotective drugs 
in acute ischaemic stroke: are we doing 
the right thing?
Jacques De Keyser, Geert Sulter and Paul G. Luiten
Ischaemic stroke is a leading cause of death and long-lasting disability. Several neuroprotective
drugs have been developed that have the potential to limit ischaemic brain damage and improve
outcome for patients.While promising results with these drugs have been achieved in animal stroke
models, all Phase III trials conducted so far indicate that these drugs have failed to live up to their
promise. Despite the limits of animal models, which cannot mimic the clinical situation, the
disappointing results of neuroprotective trials might largely be due to methodological problems.
Future trials with neuroprotective drugs should be performed in stroke (care) units,after sufficient
information regarding therapeutic time window, dosage, duration of therapy and safety has been
gathered from pilot studies, and a better selection of target patients has been made. Much of this
information can now be obtained by techniques that visualize the penumbra, such as combined
diffusion-weighted and perfusion MRI.Consideration should also be given to clinical trials with well-
designed combinations of treatments.
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NMDA-receptor antagonist that acts as an open-channel
blocker, have been studied in Phase III trials. However,
the trials were terminated prematurely because of an
unfavourable risk–benefit ratio11.
Eliprodil is a drug that is believed to reduce the action
of glutamate by binding to the polyamine site of the
NMDA receptor1. Results were promising in Phase II
trials, but a Phase III trial was halted because sequen-
tial efficacy analysis did not demonstrate a significant
difference from placebo30.
Clomethiazole is an anti-epileptic drug that causes
neuronal hyperpolarization by enhancing the activity
of GABA at GABAA-receptors. The rationale behind its
use is that it could inhibit ischaemia-induced neuronal
depolarizations and counteract the actions of gluta-
mate. The drug protected against ischaemic cell damage
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Focal decrease of cerebral blood flow (CBF) to below 8–10 ml/100
mg/min produces rapid neuronal cell death. However, between this
densely ischaemic core and the normally perfused brain (CBF of
50–55 ml/100 mg/min), there exists a zone of moderately reduced
blood flow, the extent of which depends on the collateral supply
from surrounding arteries. In this zone, called the penumbra, O2
delivery becomes insufficient to allow normal levels of oxidative
metabolisma,b. This produces lactic acidosis and curtails the production
of ATP, the energy source of cellular ionic pumps. Failure of the Na1–K1
pump results in a rapid loss of K1 from the neurones and massive
neuronal depolarization occurs. This opens voltage-sensitive Ca21
channels and leads to an extracellular build up of excitatory amino
acids, which overstimulate excitatory-amino-acid receptorsa–c. Acute
elevation of glutamate activates the abundant number of glutamate
receptors of which, notably, the NMDA and AMPA receptors are
clearly implicated in the neurotoxic process. AMPA-receptor activation
contributes to the depolarization that is held responsible for the lift of
the Mg21 block of the NMDA-receptor channel, which subsequently
opens and allows a sustained influx of Ca21 (Ref. c).
When ATP-dependent efflux of Ca21 and active uptake of Ca21 by
the mitochondria, endoplasmic reticulum or nuclear envelope fails,
Ca21 levels will remain elevated, producing a range of consequences.
One pathway of cytotoxic Ca21 leads to generation of reactive oxygen
species via activation of NOS and the formation of excessive
amounts of NO. Elevated Ca21 in mitochondria uncouples oxidative
phosphorylation, which leads to further decrease of energy supply
and increase of free radicals. These free radicals damage cellular
membranes by lipid peroxidation. A second cytotoxic pathway that
is activated as a result of Ca21 overload leads to the sustained acti-
vation of a large range of Ca21-dependent enzymes, such as lipases,
proteases, endonucleases and other catabolic enzymes that collec-
tively have detrimental consequences for cell function, membrane
structure and the cytoskeleton, and ultimately lead to necrosis.
Cell death in the ischaemic penumbra is, in part, also the result
of apoptotic processes. DNA damage via endonucleases or free radicals
triggers a complex self-destructive process involving gene expressiond.
As a consequence neurones die apoptotically. There is growing evi-
dence that mitochondria are key structures for induction of this pro-
grammed cell deathe. Moderate reductions of mitochondrial ATP pro-
duction can trigger apoptotic mechanismsf. Recent studies point to
the release of caspases, cytochrome c and apoptosis-inducing factor
from mitochondria as initiators of apoptotic cell deathg.
When blood flow is restored, oxygen can enhance the biochemical
reactions that generate free radicals. Another component that con-
tributes to cell damage is inflammation. In the ischaemic zone, endo-
thelial adhesion receptors are upregulated and white cells adhere to
the wall of blood vessels, invade the parenchyma and release cytotoxic
cytokines, such as tumour necrosis factor a, interleukin (IL) 1, and IL6
(Ref. h). In conclusion, ischaemic brain damage is multidimensional
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Box 1. Neurotoxic cascade in ischaemic brain injury
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Fig. I. Neurotoxic cascade in the ischaemic penumbra. A complex neurotoxic
cascade is triggered by a focal deficit in brain perfusion. Key events are uncon-
trolled neuronal depolarizations, an overexcitation of glutamate receptors, a
build up of intracellular Ca21 levels, the generation of free radicals, the stimula-
tion of several catabolic enzyme systems and the induction of inflammation.
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in animal models of permanent and transient focal
brain ischaemia31,32. A large Phase III trial, involving 1350
patients, produced negative results12. A post hoc analy-
sis suggested a beneficial effect in patients with severe
stroke (total anterior circulation syndrome), which was
the reason for initiating a new trial, the North American
Clomethiazole Acute Stroke Study-Ischaemia (CLASS-I).
This study aims to include 1200 patients with a total
anterior circulation syndrome.
NO-pathway inhibitors and free-radical scavengers
The neuroprotective effects of lubeluzole can be ex-
plained, at least partially, by a downregulation of the
NO synthase (NOS) pathway, which reduces NO-related
neurotoxicity33. In a small Phase II trial, a dose of 7.5 mg
lubeluzole given within 6 h of the first symptoms, fol-
lowed by 10 mg per day for five days, was associated
with reduced mortality. A double-dose regimen, which
yielded a plasma concentration equivalent to the levels
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TABLE 1. Major completed Phase III trials with neuroprotective drugs in acute ischaemic stroke
Drug Class Trial Time Duration of Result Ref.
window treatment
Fosphenytoin Na1-channel antagonist 4 h 3 days No improvement of functional 2
outcome at 3 months
Nimodipinea Ca21-channel antagonist TRUST 48 h 21 days No improvement of neurological 3
outcome at 6 months
American Nimodipine 48 h 21 days No difference in mortality or 4
Study Group neurological outcome at 21 days
German–Australian 48 h 21 days No improvement of neurological 5
Stroke Trial outcome at 21 days
Nimodipine in Acute 48 h 21 days No improvement of neurological 6
Ischemic Hemispheric and functional outcome at 
Stroke 12 months
NEST 48 h 21 days No improvement of neurological 7
and functional outcome at 3 months
INWEST 24 h 21 days Unfavourable outcome in the 8
nimodipine groups
VENUS 6 h 10 days No improvement of functional 9
outcome at 3 months
Flunarizine Ca21-channel antagonist FIST 24 h 4 weeks No improvement of neurological and 10
functional outcome at 6 months
Selfotel Competitive NMDA- ASSIST 6 h bolus Unfavourable risk–benefit ratio 11
(CGS 19755) receptor antagonist
Cerestat Non-competitive NMDA- 6 h 4 h Unfavourable risk–benefit ratio Unpublished
(CNS 1102) receptor antagonist
Eliprodil Polyamine-site antagonist 8 h 14 days No improvement of functional Unpublished
at the NMDA receptor outcome at 3 months
Clomethiazole Enhances the effect of GABA CLASS 12 h 24 h No improvement of functional 12
at the GABAA-receptor outcome at 3 months
Lubeluzole NO-pathway modulator LUB-INT-9 6 h 5 days No reduction in mortality at 3 months 13
LUB-INT-5 6 h 5 days No reduction in mortality at 3 months 14
LUB-INT-13 6–8 h 5 days No improvement of functional 15
outcome at 3 months
Tirilazad Free-radical scavenger RANTASS 6 h 3 days No improvement of functional 16
outcome at 3 months
TESS 6 h 3 days No improvement of functional 17
outcome at 3 months
Ebselen Free-radical scavenger Ebselen in Acute 48 h 2 weeks No improvement of functional 18
Stroke outcome at 3 months
Ganglioside Natural constituent of the cell EST 5 h 21 days No improvement of neurological 19
GM1 membrane and functional outcome at 4 months
SASS 48 h 28 days No improvement of survival, 20
neurological and functional outcome
at 3 months
Citicholine Natural constituent of the cell Citicholine in Acute 24 h 6 weeks No improvement of functional 21
membrane Ischemic Stroke outcome at 3 months
Piracetam Acts at the cell membrane PASS 12 h 12 weeks No improvement of neurological 22
and elevates cAMP levels outcome at 4 weeks
Enlimomab Murine antibody to endothelial EAST 6 h 5 days Unfavourable risk–benefit ratio 23
adhesion molecule 1
aOnly trials enrolling more than 250 patients are listed.
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associated with neuroprotection in rats, was associated
with increased mortality36. Although this was probably
caused by an imbalance of randomization that was un-
related to the drug, three large Phase III trials of lubelu-
zole, involving 3177 patients, were conducted with the
7.5 mg dose. All three trials failed to demonstrate a
beneficial effect of lubeluzole on the primary outcome
parameters13–15, and further clinical development has
been abandoned (T. Wessel, pers. commun.).
Tirilazad is a non-glucocorticoid 21-aminosteroid
lipid-peroxidation inhibitor that acts as a free-radical
scavenger. In animals treated within 10–15 min of focal
ischaemia this drug reduced infarct volume13. However,
it did not improve overall functional outcome in two
large Phase III studies16,17. Because it was suggested that
the lack of efficacy might be caused by the use of a dose
that was too low (6 mg/kg/day for 3 days), higher doses
were tested. These trials were stopped prematurely be-
cause of safety problems and further clinical study of
tirilazad in ischaemic stroke has been suspended37.
The seleno–organic compound, ebselen, which has
antioxidant activity through a glutathione-peroxidase-
like action, was studied in Japan. This drug appeared
to improve outcome at one month, but not at three
months after the start of treatment18. Further efficacy
studies with this compound might be justified.
Drugs that mainly act at the cell membrane
In preclinical studies, the ganglioside, GM1, conferred
protection against ischaemic and excitotoxic insults38.
However, two major Phase III trials produced negative
results19,20. Because of concerns regarding a possible
association with the development of Guillain–Barré
syndrome30, GM1-ganglioside product licences have
been suspended.
After a number of small inconclusive clinical trials
with citicholine (cytidine-5-diphosphocholine or CDP-
choline), a multicentre dose-finding study in the USA
suggested a better functional outcome in stroke patients
receiving 500 mg citicholine per day given orally for six
weeks39. However, this result could not be reproduced
in a pivotal trial involving 394 patients21.
Piracetam is another compound that mainly acts on
cell membranes of both neurones and blood cells40. A
placebo-controlled multi-centre study in Europe failed
to show an improved outcome at three months22. Post
hoc analysis suggested an improvement in neurologi-
cal outcome in a subgroup of patients treated with
piracetam within 6 h of the onset of stroke. A new
Phase III trial, PASS-2, has recently been initiated in
order to confirm these results.
Anti-inflammatory agents
Within hours, endothelial adhesion molecule 1
(ICAM1) levels are increased in the zone of focal cer-
ebral ischaemia, which allows an influx of white cells
into the ischaemic brain area. Cytokines released from
the invaded white cells contribute to brain-tissue 
damage. ICAM1 antibodies reduced infarct volume in
rats, only when the model included reperfusion, but
not with permanent middle-cerebral-artery occlusion41.
Enlimomab, a murine monoclonal antibody against
ICAM1, has been studied in a Phase III trial. Yet again,
the results in the clinical situation did not fulfil the ex-
pectations generated in the laboratory23. There was even
a trend for early neurological deterioration in patients
receiving active treatment. A probable explanation is
that the murine antigens present in the enlimomab
preparation themselves provoked an inflammatory re-
sponse that cancelled out any beneficial effects by raising
body temperature.
Why were the trials negative?
Animal models
Because all the Phase III stroke trials with neuropro-
tective drugs have failed to live up to their promise, one
could argue that the animal models that have been
used to test these substances have no predictive value.
Focal ischaemia models can be broadly categorized into
two types: permanent and reversible42. In patients, both
types of focal brain ischaemia can occur43,44. Both forms
of insult can produce a potentially salvageable penum-
bra. In the transient-occlusion model, reperfusion injury
also adds to the damage. For most of the drugs men-
tioned above, neuroprotective activity has been demon-
strated in different types of animal models, including
permanent and reperfusion models of middle-cerebral-
artery occlusion. However, animal models will never
mimic the clinical situation and, therefore, these mod-
els should be regarded merely as a method to screen
whether a particular compound has the ability to res-
cue neurones in the ischaemic penumbra when admin-
istered after the insult. Although these animal models
are indispensable when investigating these compounds,
experiments designed to measure functional outcome
three months after the ischaemic insult in a larger num-
ber of animals, as required for Phase III trials in patients,
cannot be justified because of ethical, practical and eco-
nomic reasons. Infarct volume, which is the most com-
monly used endpoint in the animal models of focal brain
ischaemia, might have little relevance to functional
outcome in patients.
Heterogeneity of the stroke population
Animal data are usually collected in healthy laboratory
rats of the same age, in which a standardized amount
of focal cerebral ischaemia is induced by a reproducible
intervention. In contrast, aetiology, location and sever-
ity of ischaemic stroke in patients is very heterogeneous.
Young and elderly patients are grouped together. It is
well known that elderly patients tend to have a worse
outcome than younger patients because they have co-
morbidities that heavily affect outcome. Some patients
have a large cortical infarction, whereas others have a
lacunar infarction with a completely different progno-
sis45. Some patients have a poor collateral circulation
and, hence, a smaller penumbra or no penumbra at
all46,47. Some patients show spontaneous reperfusion in
the early stages after stroke and tend to have a better
clinical outcome than those without reperfusion43. It is
also hardly surprising that no benefit can be demon-
strated when an operation designed to correct a par-
ticular pathophysiological disturbance is performed in
a group of patients, many of whom do not have that
disturbance. For example, one in four patients enrolled
in a trial with clomethiazole had lacunar white-matter
infarctions12, where there are no neuronal GABAA
receptors to be stimulated.
Other factors that could aggravate brain damage
In animal studies, other variables might affect infarct
size and outcome, such as blood pressure, body tempera-
ture and oxygenation, which are all carefully con-
trolled during the experiments. It is known that a re-
duction in blood pressure, hyperglycaemia, hypoxia and
increased body temperature can all aggravate cerebral
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damage48,49, and might override any beneficial effect of
a neuroprotective agent50. However, protocol-specified
management of these variables has been neglected in
all Phase III stroke trials conducted so far.
Therapeutic dose and adverse effects
Doses of neuroprotective drugs that limit infarct size
in animals are usually associated with adverse effects
that can limit tolerable doses and prohibit their clinical
use. Psychomimetic side-effects were the main reason
for the premature termination of trials with NMDA-
receptor antagonists. Some side-effects clearly override
the putative beneficial effect of a neuroprotective drug.
Examples are the detrimental haemodynamic conse-
quences of intravenous nimodipine8 and an inflam-
matory reaction associated with the administration of
enlimomab23. Normally, such problems should be de-
tected in properly conducted Phase II trials, but there
is often so much pressure from senior management in
pharmaceutical companies to rush for registration that
well-conducted Phase II trials are often neglected.
In some trials, suboptimal doses are used because too
much emphasis is placed on safety aspects, although
side-effects might be acceptable or properly controlled
in an acute care setting. This could account for the fail-
ure of lubeluzole, where a possible misinterpretation of
limited Phase II data and concerns about QTc-interval
prolongation on the ECG led to the decision to use a
dose regimen that was probably below its neuropro-
tective threshold13–15,36. Another problem is that side-
effects can limit the duration of treatment with a neuro-
protective drug. Although it is not known exactly how
long neuroprotective therapies should last, fear of side-
effects, such as sedation, can shorten the duration of
treatment to levels that are insufficient for protecting
the penumbra. For example, clomethiazole was admin-
istered for 24 h (Ref. 12), although it had been demon-
strated that excitatory-amino-acid levels in the ischaemic
area could remain grossly elevated for at least six days
after the onset of stroke51.
Therapeutic time window
In many animal studies some drugs are effective only
if given before or very early (between 15 min and 2 h)
after the insult. Typical examples are nimodipine, 
tirilazad and NMDA-receptor antagonists16,26,52. Other
compounds, such as lubeluzole, are still effective in
reducing ischaemic brain damage when given up to 
6 h after the onset of ischaemia34,35.
Although the penumbra in humans can exist for a
longer period than in rodents, at least up to 48 h in
studies using PET (Ref. 53) and perhaps several days 
in studies using magnetic-resonance spectroscopy54,
post hoc analyses of a number of trials suggest possible
benefit in subgroups of patients treated within a shorter
therapeutic time window than defined in the proto-
col20,22,27. Because cell loss in the penumbra is a progres-
sive process, it is expected that the sooner a neuropro-
tective drug is given, the better the results that will be
obtained. A therapeutic effect might have been missed
in studies that allowed long inclusion times.
Future prospects
In view of the fact that it is not possible to translate
from the animal model to the clinical situation, it
appears that the overall disappointing results of clini-
cal trials that have accumulated over the past decade
are probably due to protocol and dosage problems.
More attention should be paid to properly conducted
Phase II trials in order to obtain sufficient information
regarding therapeutic time window, dosage, duration of
therapy and safety. In small sample sizes of patients, this
information might be obtained by invoking surrogate
parameters. These include imaging techniques that visu-
alize a potentially salvageable penumbra, such as com-
bined diffusion weighted and perfusion MRI (Refs 47,
55–57), and perhaps the determination of serum levels
of enzymes that are released during the course of
ischaemic brain damage, such as neurone-specific eno-
lase and S100 (Ref. 58). No compromise should be made
with respect to reducing the dosage or duration of treat-
ment below the therapeutic threshold in order to avoid
side-effects.
Although there is evidence that the penumbra in
humans can exist for a longer period than in rodents,
the animal experiments indicate that treatment should
be started within the first few hours in order to have
any chance of success. Neuroprotective drugs should be
administered as long as the ischaemic cascade occurs,
which can be as long as six days51,54. In addition, physi-
cians should realize that the administration of a neuro-
protective drug alone is not sufficient to improve patient
outcome. It is difficult to accept that in pivotal stroke
trials patients are still dying from aspiration pneumo-
nia because some centres do not use a protocol for the
prompt detection of swallowing difficulties. Failure to
treat elevated body temperature can also counteract the
beneficial effects of a neuroprotective drug50,59. Thus,
optimal standard care is a prerequisite for the success
of a stroke trial, and, therefore, pivotal trials with neuro-
protective drugs should be performed in stroke (care)
units48,49,60. In addition, we should abandon the unreal-
istic idea that a pharmacological intervention in stroke
should be applicable to all stroke types. Neuroprotective
trials should be conducted in patients who are likely
to have the pathophysiological disturbance that the
compound was designed to treat. By using combined
diffusion-weighted and perfusion MRI we should be
able to identify more rationally appropriate candidates
for neuroprotective therapies.
Combination therapy
All neuroprotective agents studied so far target a
specific pathway of the ischaemic cascade. It is evident
that the administration of either an NMDA-receptor
antagonist or a voltage-dependent Ca21-channel blocker
will not be able to control excessive neuronal Ca21
accumulation completely. Although these compounds
can reduce infarct size in animal models, we should
not expect that any single drug that interferes with a
specific event in the ischaemic cascade will have a
large clinical impact. In fact, the effects might not be
measurable with the crude clinical outcome measures
that are currently used, such as the Modified Rankin
Scale, the Glasgow Outcome Scale or the Barthel Index.
Instead of continuing with single drug trials (Table 2),
it might be more rewarding to explore treatments using
a combination of reperfusion with neuroprotection and
a cocktail of carefully selected neuroprotective drugs.
Animal studies have shown that combination therapies
have synergistic effects. Examples are the combination
of lubeluzole and diaspirin-crosslinked haemoglobin61;
thrombolysis with recombinant tissue plasminogen ac-
tivator (r-tPA) and a glutamate-receptor antagonist62,63;
and the combination of a glutamate-receptor antag-
onist (MK801) with basic fibroblast growth factor64,
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nimodipine65, GABA-receptor agonists66, tirilazad mesyl-
ate67 or citicholine68. However, this approach would
mean that pharmaceutical companies would have to
work together instead of competing with each other and
that the authorities have to agree to conduct trials with
compounds that have not shown efficacy on their own,
with the exception of the thrombolytic drug, r-tPA,
which is beneficial in a small number of ischaemic
stroke patients69,70.
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TABLE 2. Acute stroke Phase III trials with neuroprotective drugs in progress
Agent Class Trial Company
GV150526 Glycine-site (NMDA-receptor) antagonist GAIN Glaxo Wellcome
Clomethiazole Enhances the effect of GABA at the GABAA-receptor CLASS-I Astra
Magnesium sulfate Blocks glutamate activity at the NMDA-receptor IMAGES None
Piracetam Acts at the cell membrane and elevates cAMP levels PASS-2 UCB
BMS-204352 K1-channel-opening compound POST-010 and POST-011 Bristol Myers–Squibb
Citicholine Natural constituent of the cell membrane Phase III trial of citicholine Interneuron 
2000 mg versus placebo Pharmaceuticals
Trofermin Binds to basic fibroblast-growth-factor receptors Phase II/Phase III trial Wyeth–Ayerst
L E T T E R S  T O  T H E  E D I T O R
In their recent article, Elaine Perry and her
co-authors1 illustrate elegantly that ACh is
one of the important neurotransmitters that
regulate consciousness. One line of reason-
ing given is that many anesthetics appear to
operate through an ACh-mediated mecha-
nism. These authors provide us with a con-
cise and useful summary of ACh-mediated
mechanisms of anesthesia. However, no
certain conclusion can be drawn about the
underlying mechanism of consciousness on
the basis of the literature that deals only with
ACh. So does a possible answer lie outside
the literature on ACh?
Stuart Hameroff2 has proposed a mecha-
nism for anesthesia that is independent of
a particular neurotransmitter. His proposal
is that anesthetic gas molecules inhibit quan-
tum states produced by endogenous Van
der Waals dispersion forces, which occur
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